Press Releases

Prescient completes integration of Uptake and Dolon under single global brand

Axplora's sustainability strategy substantiated by SBTi as company accelerates action across its manufacturing network

CPHI launches new Sustainability Summit as pharma faces growing pressure to deliver sustainability goals

Philips selects Blue Spark for continuous temperature monitoring in new connected care strategy

As advances in oncology, cell and gene therapy, and other complex treatments increasingly move care beyond traditional inpatient settings, the ability to continuously monitor patients for early signs of complications is becoming increasingly important. Philips announced a new strategy to expand its open patient monitoring ecosystem through collaborations with select wearable and out-of-hospital technology companies -- including Blue Spark Technologies, which was selected for its best-in-class continuous core body temperature monitoring technology. Blue Spark's TempTraq® wearable patch provides continuous core body temperature monitoring and has been clinically tested in more than 30 studies. Research has demonstrated its ability to detect fevers earlier than routine intermittent temperature monitoring -- an important distinction for patient or clinical trial populations where subtle temperature changes can provide an early warning of infection, inflammation, treatment-related complications, or clinical deterioration.

ECI’s Product & Packaging Testing Laboratory Achieves ISO/IEC 17025 Accreditation

ECI announced today that its Product & Packaging Testing Laboratory, located in the Coyol Free Zone in Costa Rica, has achieved ISO/IEC 17025:2017 accreditation from A2LA for technical competence in mechanical testing.

Sanofi’s MenQuadfi Wins EU Approval for Infants from Six Weeks Against Meningococcal Disease

Sanofi’s MenQuadfi has received European Commission approval for use in infants from six weeks of age against invasive meningococcal disease caused by serogroups A, C, W and Y. The expanded indication is supported by the MET58 pivotal study and clinical data involving more than 6,000 infants across 11 countries. The approval provides EU healthcare professionals with another option for early protection against a rapidly progressing and potentially fatal infection.

CellCarta Adds Tempus to CDx Commercialization Lab Network

CellCarta today announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM).

Headlands Research Expands Pacific Northwest Presence with New Clinical Research Site in Bellingham, Washington

Led by a board-certified psychiatrist and 2025 APA Fellow, Headlands Research's new purpose-built site gives sponsors access to more than 615,000 participants in an untapped CNS research market

Verista Announces Appointment of Michael Laferrera as Chief Executive Officer

Verista names seasoned healthcare and pharma services leader as CEO to drive strategic growth, innovation, and operational excellence.

TrialAssure® ANONYMIZE® Selected by the European Medicines Agency as Official Anonymisation Tool

TrialAssure® announced today that its ANONYMIZE® platform has been selected by the European Medicines Agency (EMA) as an official anonymisation tool used within the Agency.

CluePoints Appoints Martin Magazzolo as Chief Commercial Officer

CluePoints, provider of leading statistical and AI-driven software solutions, has appointed Martin (Marty) Magazzolo as its new Chief Commercial Officer (CCO).

ELRIG Appoints Drs Hitesh Sanganee and Marcus Schindler to Scientific Advisory Board

Leadership expansion reinforces ELRIG's commitment to delivering impactful drug discovery initiatives and driving community-wide collaboration

Acrosian Launches as AI-Era Biometrics CRO, Built by the Team Behind One of the Industry’s Largest Independent Biometrics CROs

Novo Nordisk Challenges Lilly’s GLP-1 Advertising Campaigns, Claiming Consumers Are Misled by Outdated Comparisons

Novo Nordisk has filed a lawsuit against Eli Lilly, claiming that Lilly’s GLP-1 advertising campaigns use outdated comparisons and mislead consumers about obesity and diabetes treatments. The dispute focuses on advertisements comparing Zepbound® and Mounjaro® with lower doses of Wegovy® and Ozempic®. Novo Nordisk is seeking removal of the campaigns and corrective advertising to ensure patients receive updated scientific information. The case highlights increasing competition between leading pharmaceutical companies in the fast-growing GLP-1 therapy market.

PumasAI Helps Launch India's First Computational Lab for Quantitative Sciences to Advance AI in Drug Development

New collaboration with PSGIMSR and SOPHAS strengthens education, research, and computational infrastructure for the next generation of clinical pharmacology and pharmacometrics leaders

Lilly to Acquire AtaiBeckley to Advance Innovative Biotech Therapies for Treatment-Resistant Depression

Eli Lilly and Company has announced a definitive agreement to acquire clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion, including milestone-based payments. The acquisition significantly expands Lilly's neuroscience pipeline with innovative rapid-acting neuroplastogen therapies for treatment-resistant depression and other serious mental health disorders. The transaction highlights growing pharmaceutical investment in next-generation psychiatric medicines designed to deliver durable symptom relief through novel mechanisms of action.

Trajan Expands US Availability of Harpera™ Microbiopsy Punch for Clinical Skin Sampling

Trajan Scientific and Medical (Trajan), a global developer and manufacturer of analytical, life sciences, and medical technologies, has announced that its Harpera™ Microbiopsy Punch is now FDA-registered for marketing in the US. Previously available in the country for investigational use only, the suture-free device can now be used by healthcare professionals across a broader range of clinical skin sampling applications, alongside clinical research and wellness programs. The registration responds to growing demand from healthcare and research organizations for patient-friendly sampling approaches, offering a minimally invasive alternative to traditional skin biopsy that reduces collection burden while preserving sample quality for modern molecular techniques. Healthcare professionals in the US now gain expanded access to a tool that supports dermatology, biomarker research, and precision medicine, with applications spanning molecular analysis, translational research, and longitudinal skin sampling.

MIB Agents Osteosarcoma Alliance Appoints Katherine Azima as Co-Director of Scientific Programs

MIB Agents Osteosarcoma Alliance, a nonprofit dedicated to Making It Better for the osteosarcoma community through research, education and patient support, today announced that Katherine Azima has joined the organization as Co-Director of Scientific Programs. In this role, Azima will work alongside Christina Ip-Toma, Co-Director of Scientific Programs, until Ip-Toma retires at the end of the year, to help lead and expand MIB Agents' growing portfolio of scientific initiatives, fostering collaboration among researchers, clinicians, industry partners and patient advocates to accelerate progress in osteosarcoma research.

Sanofi Wins FDA Approval for First On-Body Injector Cancer Treatment, Making Multiple Myeloma Care Simpler

The FDA has approved Sanofi's Sarclisa Escena, making it the first anticancer therapy that can be administered through a wearable on-body injector. Clinical studies showed the new subcutaneous treatment delivers effectiveness comparable to intravenous therapy while reducing administration time and infusion-related reactions. The approval is expected to improve both patient convenience and healthcare workflow in the treatment of multiple myeloma.

Novogene Europe Launches Untargeted Metabolomics Service at Cambridge Omics Centre

• Strengthens multiomics portfolio offering metabolite-level insight to connect molecular data with biological function across broader life science studies • New workflow built around Thermo Scientific Vanquish UHPLC coupled with Orbitrap Exploris 120 high-resolution accurate-mass mass spectrometry